Ranolazine interactions

Full monograph for Ranolazine Check it against another medicine

Medicines

454 documented

Severity

Mechanism

Medicines documented to interact with Ranolazine, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Amiodarone Hydrochloride	Major	Synergy	Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related…	45 sources — open the full entry
Amisulpride	Major	Synergy	Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the…	3 sources — open the full entry
Amlodipine Besilate + Atorvastatin	Major	Metabolism · Unknown	Coadministration with ranolazine may increase the plasma concentrations of atorvastatin and potentiate the risk of statin-induced myopathy. The mechanism…2 documented mechanisms	84 sources — open the full entry
Apalutamide	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Aprepitant	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Armodafinil	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Arsenic Trioxide	Major	Synergy	Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the…	4 sources — open the full entry
Artemether + Lumefantrine	Major	Synergy	Artemether-lumefantrine may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…2 documented mechanisms	16 sources — open the full entry
Atorvastatin + Ezetimibe	Major	Metabolism · Unknown	Coadministration with ranolazine may increase the plasma concentrations of atorvastatin and potentiate the risk of statin-induced myopathy. The mechanism…2 documented mechanisms	84 sources — open the full entry
Atorvastatin Calcium	Major	Metabolism	Coadministration with ranolazine may increase the plasma concentrations of atorvastatin and potentiate the risk of statin-induced myopathy. The mechanism…	84 sources — open the full entry
Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Betamethasone + Clotrimazole	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Betamethasone + Clotrimazole + Gentamicin	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Betrixaban	Major	Others	Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the plasma concentrations of betrixaban, which is a substrate of the…	11 sources — open the full entry
Bosentan Monohydrate	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Brexpiprazole	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these…	5 sources — open the full entry
Cabozantinib	Major	Synergy	Cabozantinib can cause prolongation of the QT interval.	7 sources — open the full entry
Calcium Dobesilate + Lidocaine + Dexamethasone	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Carbamazepine	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Cenobamate	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Ceritinib	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ranolazine, which is primarily metabolized by the…	7 sources — open the full entry
Chloroquine Phosphate	Major	Synergy	Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong…	22 sources — open the full entry
Ciprofloxacin + Dexamethasone	Major	Metabolism · Synergy	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.2 documented mechanisms	19 sources — open the full entry
Citalopram Hydrobromide	Major	Synergy	Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	15 sources — open the full entry
Clarithromycin	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ranolazine, which is primarily metabolized by the…	7 sources — open the full entry
ClotrimazoleEar drop Eye ointment Topical Vaginal tablet	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Clotrimazole + Hydrocortisone	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Colchicine	Major	Excretion	Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced…	78 sources — open the full entry
Crizotinib	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Dexamethasone	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Dexamethasone + Chloramphenicol	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Dexamethasone + Levofloxacin	Major	Metabolism · Synergy	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.2 documented mechanisms	19 sources — open the full entry
Dexamethasone + Neomycin + Glacial Acetic Acid	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Dexamethasone + Tobramycin	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Diltiazem Hydrochloride	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Efavirenz	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Enzalutamide	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
ErythromycinLotion Oral	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Escitalopram Oxalate	Major	Synergy	Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	13 sources — open the full entry
Esomeprazole + Amoxicillin + Clarithromycin	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ranolazine, which is primarily metabolized by the…	7 sources — open the full entry
Fluconazolebase Ophthalmic	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Fluvoxamine Maleate	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because…	4 sources — open the full entry
Fosphenytoin Sodium	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Gatifloxacin	Major	Synergy	Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…	28 sources — open the full entry
Gatifloxacin + Dexamethasone	Major	Metabolism · Synergy	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.2 documented mechanisms	40 sources — open the full entry
Griseofulvin [Ultra Microsize]	Major	Metabolism	Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.	12 sources — open the full entry
Haloperidol	Major	Synergy	Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	14 sources — open the full entry
Hydroxychloroquine Sulphate	Major	Synergy	Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong…	22 sources — open the full entry
Iloperidone	Major	Synergy	Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…	9 sources — open the full entry

Food & lifestyle

grapefruit juice
Major
Metabolism
Grapefruit and grapefruit juice may significantly increase the plasma concentrations of orally administered ranolazine. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Because ranolazine prolongs QT interval in a dose-dependent manner, high plasma levels of ranolazine may increase the risk of ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, and torsade de pointes.
What to do: Patients treated with ranolazine should avoid consumption of grapefruit juice and other grapefruit products if possible. Otherwise, the dosage of ranolazine should be limited to 500 mg twice a day.
1 source
1. "Product Information. Ranexa (ranolazine)." Calmoseptine Inc (2006):

Conditions

Conditions in which Ranolazine needs care, as documented in this source.

Liver Failure
Major
Plasma concentrations of ranolazine increased by 30% in patients with mild (Child-Pugh Class A), and by 60% in patients with moderate (Child-Pugh B) hepatic impairment. The use of ranolazine is contraindicated in patients with clinically significant hepatic impairment.
1 source
1. "Product Information. Ranexa (ranolazine)." Calmoseptine Inc (2006):
Kidney Diseases
Moderate
In patients with varying degrees of renal impairment, ranolazine plasma levels increased up to 50%, Caution is advised when used in patients with renal impairment. The pharmacokinetics of ranolazine has not been assessed in patients on dialysis.
1 source
1. "Product Information. Ranexa (ranolazine)." Calmoseptine Inc (2006):
Long QT Syndrome
Moderate
Ranolazine prolongs the QT interval in a dose-related manner. Caution should be exercised if used in patients with long QT interval, or using other QT- prolonging drugs.
1 source
1. "Product Information. Ranexa (ranolazine)." Calmoseptine Inc (2006):

Medicines

Food & lifestyle

grapefruit juice

Conditions

Liver Failure

Kidney Diseases

Long QT Syndrome